Abstract
A significant number of patients infected with the new coronavirus suffer from chronic fatigue syndrome after COVID-19, and their symptoms may persist for months after the infection. Nevertheless, no particular treatment for post-disease fatigue has been found. At the same time, many clinical trials have shown the effectiveness of l-carnitine in relieving fatigue caused by the treatment of diseases such as cancer, MS, and many other diseases. Therefore, it can be considered as a potential option to eliminate the effects of fatigue caused by COVID-19, and its consumption is recommended in future clinical trials to evaluate its effectiveness and safety.
All Keywords
【저자키워드】 angiotensin-converting enzyme 2, renin-angiotensin system, interleukin, chronic fatigue syndrome, Paraventricular Nucleus, ILInterleukin, ACE2angiotensin-converting enzyme 2, RASRenin-angiotensin system, CFSChronic fatigue syndrome, PVNparaventricular nucleus, 【초록키워드】 COVID-19, Treatment, clinical trial, fatigue, Cancer, Infection, Symptom, Patient, Effectiveness, disease, New coronavirus, other diseases, Effect, shown, evaluate, caused, 【제목키워드】 reduce, Can,
【저자키워드】 angiotensin-converting enzyme 2, renin-angiotensin system, interleukin, chronic fatigue syndrome, Paraventricular Nucleus, ILInterleukin, ACE2angiotensin-converting enzyme 2, RASRenin-angiotensin system, CFSChronic fatigue syndrome, PVNparaventricular nucleus, 【초록키워드】 COVID-19, Treatment, clinical trial, fatigue, Cancer, Infection, Symptom, Patient, Effectiveness, disease, New coronavirus, other diseases, Effect, shown, evaluate, caused, 【제목키워드】 reduce, Can,